Trial Profile

Oral Anti-CD3 for the Treatment of Active Ulcerative Colitis

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Muromonab CD3 (Primary) ; Omeprazole
Indications Ulcerative colitis
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

24 Jun 2019 According to a Tiziana Life Sciences media release, this study was conducted in Harvard Medical School, also.
24 Jun 2019 According to a Tiziana Life Sciences media release, this study were published at in the peer reviewed journal Crohns & Colitis 360.
09 May 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com